Advertisement

Volume 131, Issue 1

 

 

January 4, 2018 – Welcome to “This Week in Blood,” a weekly snapshot of the hottest studies from each week’s issue of Blood, the official journal of the American Society of Hematology (ASH), hand-picked by Blood Editor-in-Chief Bob Löwenberg, MD, PhD, and Deputy Editor Nancy Berliner, MD.

Cover Figure: Discovery of donor B-cell antibodies against AML in transplant recipients. See the article by Gillissen et al.

Reclassifying patients with early-stage Hodgkin lymphoma based on functional radiographic markers at presentation
Using a large data set, the investigators define clinically useful prognostic risk profiles and distinguish early-stage favorable and unfavorable Hodgkin lymphoma based on metabolic tumor volume and total lesion glycolysis on baseline positron emission tomography.


LEDGF/p75 is dispensable for hematopoiesis but essential for MLL-rearranged leukemogenesis
Lens epithelium–derived growth factor (LEDGF/p75; encoded by the PSIP1 gene) is required for leukemic transformation potential of mixed lineage leukemia (MLL)–fusion proteins. This study provides evidence that LEDGF/p75 is not critically required for self-renewal of hematopoietic stem cells and that LEDGF could be a key therapeutic target in MLL-fusion leukemias.


Development of T-cell immunotherapy for hematopoietic stem cell transplantation recipients at risk of leukemia relapse
The development of adoptive cell therapies for myeloid diseases has not advanced to the same degree as anti-CD19 chimeric antigen receptor (CAR) T-cell therapies. This is the first report of an engineered T-cell receptor transgenic T-cell construct specifically designed to target minor histocompatibility antigens for the treatment of leukemia in the context of allogeneic stem cell transplantation.


Infectious complications of CD19-targeted chimeric antigen receptor–modified T-cell immunotherapy
The investigators report the first study systematically analyzing infectious complications in patients with relapsed or refractory B-cell malignancies after treatment with CD19-targeted CAR T cells.


AML-specific cytotoxic antibodies in patients with durable graft-versus-leukemia responses
In a provocative study, the investigators describe the discovery of donor B-cell derived cytotoxic antibodies, isolated from allogeneic hematopoietic cell transplant patients with acute myeloid leukemia (AML) in sustained remission, which target the spliceosome U5 snRNP200 complex expressed on the cell surface of AML blasts.


Platelets from donors with consistently low HLA-B8, -B12, or -B35 expression do not undergo antibody-mediated internalization
The investigators report low-level expression of MHC on platelets is relatively consistent over time within a given donor. That these platelets with low-level expression are not efficiently opsonized and internalized by macrophages has important clinical implications for donor selection for refractory patients.


Introduction to a series of reviews on therapeutic antibodies
Introduced by Drs. Freda K. Stevenson and Catherin M. Bollard, this series of 6 reviews written by leaders in the field describe the emerging mechanistic insights and therapeutic value of different classes of antibody therapy, including direct antibodies; “accelerator” antibodies against coreceptors; and antibodies reversing regulatory T-cell activity, for a variety of hematological malignancies.

The articles in this review series, "Therapeutic Antibodies", include the following:

 

View this week's complete table of contents

Why Submit to Blood?

 


Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field of hematology, is available weekly in print and online. Blood is the official journal of the American Society of Hematology (ASH) (www.hematology.org), the world’s largest professional society concerned with the causes and treatment of blood disorders.

ASH’s mission is to further the understanding, diagnosis, treatment, and prevention of disorders affecting blood, bone marrow, and the immunologic, hemostatic, and vascular systems by promoting research, clinical care, education, training, and advocacy in hematology.

blood® is a registered trademark of the American Society of Hematology.